Rheumatoid Arthritis
Conditions
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Research subjects should meet the following diagnostic criteria: ? Western medicine diagnostic criteria: comprehensive judgment using the 2010 ACR / EULAR RA classification standard; ? TCM syndrome types meet the diagnostic criteria of wet syndrome recognized by experts (2) According to the DAS28-CRP score, patients whose disease is in a low activity period (2.6 <DAS28-CRP <3.2); (3) The age is 18 ~ 70 years old; (4) Have not been treated with disease-modifying antirheumatic drugs (DMARDs), or have previously received DMARDs, but have not used such drugs for at least one month; (5) A written informed consent form signed by a family member (guardian) with hypertension who agreed to participate in this trial.
Exclusion criteria
Exclusion criteria: Patients who meet or expect to meet any of the following criteria will not be allowed to participate in this study: (1) history of other autoimmune diseases, such as Sjogren's syndrome and systemic lupus erythematosus; acute or chronic infectious diseases, including hepatitis B or hepatitis C infection; past history of cancer; evidence of active, latent or improperly treated Mycobacterium tuberculosis infection; (2) Patients with severe cardiovascular, brain, lung, liver, kidney and hematopoietic diseases; (3) Pregnant women, lactating women or patients with known mental disorders; (4) Patients with hemoglobin level less than 90 g/L, white blood cell count less than 3.0 *10^9/L, or platelet count less than 100 *10^9/L; (5) Patients whose glomerular filtration rate is lower than 40 ml/min; (6) The level of aspartate aminotransferase or alanine aminotransferase was 1.5 times higher than the upper limit of normal range. (7) Patients with active gastroduodenal ulcer or gastritis caused by long-term use of NSAIDs; (8) Patients allergic to experimental drugs; (9) Screening patients who participated in other clinical trials within 4 weeks. (10) Patients with damp-heat syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RF;CCP;DAS28;ACR20 remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| ESR;CRP;MRI evaluation of the involved joint;Joint symptoms and signs;General symptoms and signs;medication safety; | — |
Countries
China
Contacts
Public ContactHuang Runyue
Outcome results
None listed